PrimaryCareNOW: A Pri-Med Virtual Conference | Pri-Med

Join your clinician colleagues and expert faculty for PrimaryCareNOW: A Pri-Med Virtual Conference, on Friday–Saturday, May 14–15.

Moderated by Pamela Kushner, MD, FAAFP, and Ty J. Gluckman, MD, FACC, FAHA, this two-day learning experience will provide you with evidence-based sessions that span the diverse therapeutic areas that touch primary care, allow opportunities for interactive Q&A, and offer timely medical updates to keep you informed on the most current clinical strategies relevant to your daily practice.

Earn up to 10.75
AMA PRA Category 1 Credits™ and 10.75 ABIM Medical Knowledge MOC Points, or 10.75 AANP contact hours of continuing education, including 1.74 hours of pharmacology, by attending the full conference. 

Your free registration includes the full conference, but feel free to join the sessions that work with your schedule. 
Agenda and details are subject to change.

To register for this virtual conference, you will be asked to sign in to your Pri-Med account. If you do not have an account, you can create your free account now, which takes less than two minutes.

Agenda

  CME/CE Accredited Session

Non-CME/CE Session
Sponsored by Industry

Click For Session Details
Session Times Listed in ET

8–9am ET    CME/CE Accredited Session

Psychiatry

 

Alcohol use frequently co-occurs with anxiety disorders, especially during the highly anxiety-provoking circumstances of the current pandemic. People increasingly self-medicate their stress with alcohol, sometimes leading to frank alcohol use disorder. Despite alcohol’s legal status and social acceptability in many countries, it remains a potentially dangerous, toxic substance. Withdrawal from alcohol can be fatal, and medically managed withdrawal is often necessary to ensure patient safety. In this presentation, we will describe the fundamental pharmacology and acute presentations of alcohol use disorder and discuss counseling approaches. We will then explore the clinical aspects of the three FDA-approved medications for its treatment: disulfiram, naltrexone, and acamprosate. We will conclude with some novel ideas about future directions in the pharmacotherapy of alcohol use disorders.

Petros Levounis, MD, MA

Professor and Chair, Department of Psychiatry, Rutgers New Jersey Medical School, Chief of Service, University Hospital, Newark, NJ

9:10–10:10am ET    CME/CE Accredited Session

Endocrinology

Managing Obesity in Primary Care Practice 

Fatima Cody Stanford, MD, MPH, MPA, FAAP, FACP, FTOS

 

Obesity is the most prevalent chronic disease of the modern era in the U.S. and around the world, affecting both the adult and pediatric population. Although many believe that helping patients to achieve a healthy weight is of minimal complexity, weight regulation and management is a challenging endeavor. In this talk, the faculty will explore the complexities of obesity and offer a range of strategies (behavioral, therapeutic, and surgical) to help you in the quest to address overweight and obesity in your practice.

Fatima Cody Stanford, MD, MPH, MPA, FAAP, FACP, FTOS

Obesity Medicine Physician Scientist, Massachusetts General Hospital and Harvard Medical School, Boston, MA

10:20–11:05am ET    Non-CME Industry Theater

Cardiology

Eugene E. Wright, MD | Kris Vijay, Kris Vijay, MD, MS, FACP, FACC, FNLA, FCRS, FHFSA

 

The objectives of the program are to: 

  • Review the interconnected nature of the CRM systems 
  • Identify the shared risk factors that contribute to the development and progression of clinically comorbid conditions within these systems
  • Discuss the impact of coexisting conditions of the CRM systems and the continuum of risk
  • Highlight a collaborative care approach for patients who are at risk for or have established disorders of the CRM systems
 

Eugene E. Wright, MD

Consulting Associate, Department of Medicine, Department of Community and Family Medicine, Duke Southern Regional Area Health Education Center (AHEC), Fayetteville, North Carolina

Kris Vijay, Kris Vijay, MD, MS, FACP, FACC, FNLA, FCRS, FHFSA

(Krishnaswami Vijayaraghavan, MD, MS, FACP, FACC, FNLA, FCRS, FHFSA)

Medical Director, CHF, Abrazo Arizona Heart Hospital and Abrazo Health Network, Clinical Professor of Medicine, University of Arizona, Adjunct Professor of Medicine, Midwestern University, Glendale, Arizona, Associate Editor, Journal of Clinical Lipidology, Past Governor, ACC Arizona, Founding Member and Past President, Cardiorenal Society of America (CRSA), Founding member and President, Twinepidemic, Inc, President, Innovative Cardiometabolic Center

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

10:20–11:05am ET    Non-CME Industry Theater

Rheumatology

Paul Sutej, MD

 

  • Understand the causes and prevalence of chronic low back pain
  • Differentiate inflammatory back pain (IBP) from mechanical back pain
  • Learn the significance of IBP as a potential early symptom of ankylosing spondylitis (AS)
  • Learn the importance of referring patients with IBP to a rheumatologist in a timely manner

Paul Sutej, MD

Sponsored by AbbVie

11:15am–12:15pm ET    CME/CE Accredited Session

Hot Topics

 

Session Overview to Come

12:25–1:25pm ET    CME/CE Accredited Session

Gastroenterology

 

This activity will provide an evidence-based approach to the diagnosis and management of irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC), with minimal diagnostic testing. The faculty will describe evidence-based treatment guidelines and discuss the efficacy of over-the-counter and prescription agents prioritized within the guidelines. This will help you navigate the progress from patient education to diet plus over-the-counter agents to prescription agents.

Philip Schoenfeld, MD, MSEd, MSc

Chief (Emeritus) - Gastroenterology Section, John D. Dingell VA Medical Center, Detroit, MI

Supported by Allergan and Ironwood Pharmaceuticals, Inc. Salix Pharmaceuticals

1:35–2:20pm ET    Non-CME Industry Theater

Cardiology

Ted Okerson, MD, FACP, FACE

 

  • Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
  • Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population
  • Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial
 

Ted Okerson, MD, FACP, FACE

Dr. Okerson currently serves as a Sr. Field Physician within the Biopharmaceuticals US Medical Team for AstraZeneca’s Division of Cardiovascular and Metabolic Diseases. Dr. Okerson has a diverse medical and scientific background, with over 15 years of full-time clinical practice and leadership experience. For the past twenty years, he has exemplified a successful transition to industry, working as a Medical Director in various aspects of the pharmaceutical industry from clinical trial design to late phase clinical development and medical affairs for various well-known companies. In his current role, Dr. Okerson educates HCPs, works across specialties for internal collaborations, and strives to improve patient care.

Sponsored by AstraZeneca Pharmaceuticals, LP

1:35–2:20pm ET    Non-CME Industry Theater

Endocrinology

Carlos Campos, MD, MPH, CDE

 

The objective of this program is to communicate the importance of addressing cardiovascular risk in patients with type 2 diabetes. The program will cover data on prevalence, morbidity, mortality, and intensive versus conventional glucose lowering on macrovascular complications. In addition, the program will review guidance from leading medical associations that is based upon completed cardiovascular outcome trials of antihyperglycemic medications in patients with type 2 diabetes.

Carlos Campos, MD, MPH, CDE

Clinical Adjunct Professor, UT Health San Antonio, San Antonio, TX

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LL

2:30–3:30pm ET    CME/CE Accredited Session

Neurology

 

One in fifty people in the U.S. has an unruptured brain aneurysm, and one ruptures every 18 minutes. Despite low frequency, brain aneurysms are high in mortality, because the lack of a timely diagnosis often leads to death. Complicating matters more, many of the symptoms are associated with other less dangerous conditions, such as influenza or stress. This session will describe the importance of early detection, since brain aneurysms are treatable via proper identification, and will highlight risk factors and populations who are most vulnerable. Faculty will also review treatment options for clinicians to recognize or use in practice. 

Christopher S. Ogilvy, MD

Director, Endovascular and Operative Neurovascular Surgery, BIDMC Brain Aneurysm Institute, Professor of Neurosurgery, Harvard Medical School, Boston, MA

3:40–4:40pm ET    Non-CME Industry Theater

Neurology

Michael Ledet, MD

 

In a presentation with Dr. Ledet, learn about the pivotal clinical data and a pilot study that evaluated the next-dose transition from a treatment to this treatment option

Michael Ledet, MD

Medical Director, Southeast Regional Center for Sleep/Wake Disorders at Springhill Medical Center

Dr. Ledet has been the Medical Director of Southeast Regional Center for Sleep/Wake Disorders at Springhill Medical Center for the past 30 years in Mobile, Alabama and is board certified in Family Medicine, Sleep Medicine, and Lipidology.

Sponsored by Eisai Inc.

3:40–4:25pm ET    Non-CME Industry Theater

Pulmonology

 

Session Overview to Come

Sponsored by AstraZeneca

8–9am ET    CME/CE Accredited Session

Geriatrics

 

With the COVID-19 Pandemic, older adults have experienced severe illness, increased hospitalizations, and mortality at alarming rates. Nursing homes and long-term care retirement communities emerged as COVID-19 hotspots with rampant outbreaks. Every older adult diagnosed with or exposed to COVID-19 have realized the potential ramifications. Providers have been at the forefront of mediating these decisions. Dr. Lindquist will discuss how long-term care and end-of-life planning has been impacted by COVID-19. Utilizing real-world examples with older adults and experiences in home-based and nursing home care, Dr. Lindquist will showcase how to prepare older adults and their loved ones for the consequences of COVID-19. 

Lee A. Lindquist, MD, MPH, MBA

Chief of Geratrics, Northwestern University Feinberg School of Medicine, Chicago, IL

Supported by Commercial Supporter here

9:10–10:10am ET    CME/CE Accredited Session

Orthopedic

 

Hip, knee, and back pain are common complaints in the outpatient setting. It is critical for primary care providers to develop an evidence-based systematic approach to address these complaints. This presentation will improve familiarity with anatomy of the hip, knee, and back through a case-based approach. Learners will be able to generate differential diagnoses for pain in the aforementioned regions and determine appropriate imaging studies using ACR 

Stephen N. Henry, DO, MS

Supported by Commercial Supporter here

10:20–11:05am ET    Non-CME Industry Theater

Gastroenterology

 

*This is a hypothetical case and not an actual patient    

Uncover the cause of the patient's symptoms in this virtual case study and consider if this could apply to any patients you manage.

 

10:20–11:05am ET    Non-CME Industry Theater

Rheumatology

Marina Magrey, MD

 

This webinar will educate primary care physicians on screening tools for assessment of axial spondyloarthritis, including referral strategies presented by the Assessment of SpondyloArthritis international Society (ASAS) and the Prevalence of Axial Spondyloarthritis (PROSpA) to help inform decisions on appropriate referrals to rheumatologists. This is the fifth chapter of a series of videos exploring early recognition of axSpA.
Join us for a live webinar with Dr. Danve and Dr. Magrey on May 15.

Marina Magrey, MD

Case Western Reserve University School of Medicine, MetroHealth Medical Center

Sponsored by Novartis

11:15am–12:45pm ET    CME/CE Accredited Session

Cardiology

Curbside Cardiology Consult: Peripheral Artery Disease and Heart Failure 

Ty J. Gluckman, MD, FACC, FAHA | Alison L. Bailey, MD, FACC, FAACVPR

 

Heart failure is a global pandemic that continues to increase in prevalence. Despite the availability of established and novel therapies, mortality and morbidity in heart failure remains high. Join us for this overview of heart failure classification and pathophysiology, the evidence base supporting various treatments, and current guideline recommendations. 

Ty J. Gluckman, MD, FACC, FAHA

Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS),, Providence Heart Institute, Providence St. Joseph Health, Portland, OR

Default Biography Avatar

Alison L. Bailey, MD, FACC, FAACVPR

Governor, Tennessee Chapter,, American College of Cardiology, Washington, DC

Supported by Commercial Supporter here

12:55–1:40pm ET    CME/CE Accredited Session

Wellness

 

Session Overview to Come

Shirah Vollmer, MD

Clinical Professor of Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA

Supported by Commercial Supporter here

1:50–2:35pm ET    Non-CME Industry Theater

Endocrinology

 

Evaluate when the guidelines recommend GLP-1 RA use for T2D treatment. Review the glucose-dependent mechanism of action, safety, and dosing of a once-weekly GLP-1 RA.  Discuss the efficacy and safety data from pivotal T2D glycemic control trials and from the cardiovascular outcomes trial

Sponsored by Novo Nordisk Inc.

1:50–2:35pm ET    Non-CME Industry Theater

Gastroenterology

Jeffrey Teckman, MD

 

This educational program will provide a practical overview of common liver diseases which may be encountered in Primary Care, such as NAFLD and NASH. Differentiation of less common hepatic pathology, such as alpha-1 antitrypsin deficiency, will be reviewed. 

Jeffrey Teckman, MD

Interim Chairman, Department of Pediatrics, Drs. Patricia & James Monteleone Endowed Chair in Pediatric Gastroenterology, Professor of Pediatrics, Professor of Biochemistry and Molecular Biology, Director of Pediatric Gastroenterology and Hepatology, Saint Louis University School of Medicine

Sponsored by Takeda Pharmaceuticals U.S.A., Inc.

2:45–4:15pm ET    CME/CE Accredited Session

Gastroenterology

Nutritional and Pharmacological Approach to IBS-D and its Masqueraders 

William D. Chey, MD, FACG, AGAF, FACP, RFF | Kate Scarlata, MPH, DRN | Neilanjan Nandi, MD, FACP

 

This symposium will provide an overview of practical diagnostic and treatment considerations for managing patients with IBS-D in the primary care setting. Diagnostic approaches for IBS-D will be reviewed in the context of conditions that commonly mimic symptoms of the disorder. Participants will learn about the latest evidence based treatment strategies for IBS-D, including nutritional approaches, behavioral therapies, and conventional and newer pharmacologic therapies.

William D. Chey, MD, FACG, AGAF, FACP, RFF

Director, GI Physiology Lab, Director, Nutrition & Lifestyle Program, Michigan Medicine, Ann Arbor, MI

Kate Scarlata, MPH, DRN

For a Digestive Peace of Mind, Medway, MA

Neilanjan Nandi, MD, FACP

Associate Professor of Clinical Medicine, Inflammatory Bowel Diseases Center, University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia, PA

4:25–5:10pm ET    Non-CME Industry Theater

Cardiology

The Continuum of Heart Failure 

Pam R. Taub, MD, FACC

 

The objective of this program is to discuss the pathophysiology, disease burden, and management of heart failure (HF). The program will present data on HF prevalence and health outcomes, review the implications of type 2 diabetes as a common comorbidity, and provide guidance on diagnosing HF. It will conclude with a brief overview of current treatment options for HF.

Pam R. Taub, MD, FACC

Associate Professor of Medicine, UC San Diego Health System, San Diego, California

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC